Description: MGC Pharmaceuticals Ltd is an EU based specialist medical cannabis company with many years oftechnical and commercial experience in the medical cannabis industry. The company's founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality nonpsychoactive cannabidiol (CBD) resin extract for the growing demand in cosmetics and medical markets in Europe, North America and Australasia. The company is also developing strategic joint ventures in these key value-add industries, as demonstrated with MGC Derma CBD cosmetics.
Home Page: mgcpharma.com.au
1202 Hay Street
West Perth,
WA
6005
Australia
Phone:
61 8 6382 3390
Officers
| Name | Title |
|---|---|
| Mr. Roby Reuven Zomer | Co-Founder, CEO, MD & Exec. Director |
| Ms. Angela-Marie Graham | Group Chief Financial Officer |
| Ms. Yifat Steuer | Deputy CEO & COO |
| Mr. Amir Polak | Chief Technology Officer |
| Ms. Nicole Ann Godresse | Global Chief Sales Officer |
| Ms. Sabina Suljakovic | Head of the Quality Assurance Department |
| Dr. Nadya Lisovoder | Chief Medical Officer |
| Ms. Sasha Friedman | Deputy CEO |
| Yair Tal | Chief Information Security Officer |
| Mr. Robert Clements | Chief Commercial Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 15.1976 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.6874 |
| Price-to-Sales TTM: | 5.8141 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |